LABU stock forecast, quote, news & analysis

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences Corp (NASDAQ:EXAS), Exelixis (NASDAQ:EXEL).

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Biotechnology Select Industry Index ("index"). The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.

The average market capitalization across the Direxion Daily S&P Biotech Bull 3X ETF ETF is 9.63B. The market cap for tickers in the group ranges from 147.12M to 322.43B. ABBV holds the highest valuation in this group at 322.43B. The lowest valued company is CABA at 147.12M.

The average weekly price growth across all stocks in the Direxion Daily S&P Biotech Bull 3X ETF ETF was 20%. For the same ETF, the average monthly price growth was 1%, and the average quarterly price growth was 23%. FATE experienced the highest price growth at 43%, while ALEC experienced the biggest fall at -30%.

The average weekly volume growth across all stocks in the Direxion Daily S&P Biotech Bull 3X ETF ETF was -14%. For the same stocks of the ETF, the average monthly volume growth was -8% and the average quarterly volume growth was -32%